Current Report Filing (8-k)
May 17 2021 - 7:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 17, 2021
9 Meters Biopharma, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-37797
|
|
27-3948465
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
8480 Honeycutt Road, Suite 120, Raleigh, NC
27615
(Address of principal executive offices) (Zip
Code)
(919) 275-1933
(Registrant’s telephone number, include
area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock $0.0001 Par Value
|
NMTR
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On May 17, 2021, 9 Meters
Biopharma, Inc. announced it received approval from the United States Adopted Names (USAN) Council to designate its long-acting GLP-1
agonist, NM-002, as Vurolenatide. A copy of such release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
9 Meters Biopharma, Inc.
|
|
|
|
|
Date: May 17, 2021
|
By:
|
|
/s/ Edward J. Sitar
|
|
|
|
Edward J. Sitar
|
|
|
|
Chief Financial Officer
|
false
0001551986
0001551986
2021-05-17
2021-05-17
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Sep 2023 to Sep 2024